About Peptone

Peptone creates small-molecule therapeutics targeting intrinsically disordered proteins that lack fixed structures and cannot be modeled by AlphaFold. These proteins drive diseases including cancer, diabetes, and inflammatory conditions, yet traditional drug discovery fails against them because it requires stable protein structures. Peptone combines experimental physics, mass spectrometry, and machine learning to model the 6,200 disordered human proteins and identify druggable pockets. Their platform helps pharmaceutical companies develop therapies against previously undruggable targets. Based in London and Bellinzona, Peptone serves drug developers, researchers, and patients facing diseases driven by disordered protein biology.